The BC Psychosis Program Biobank and Database for Genetic Polymorphisms and Their Associations With Psychosis Disorder

• Conditions: Psychosis; Schizophrenia
• Interventions: Genetic: Blood samples for whole genomic/transcriptomic sequencing

• Registration Number: NCT02322918
• Lead Sponsor: University of British Columbia

Brief Summary

The purpose of this study is to determine if candidate polymorphisms in brain-derived neurotrophic factor (BDNF) and catechol-o-methyl transferase (COMT) are predictive of psychosis disorder severity, symptomology, and resolution in patients at BCPP. A secondary objective will be to form a biorepository of blood and saliva samples from patients at BCPP so that further genetic, proteonomic and pharmacogenomic studies may be done to gain insight into the genetic basis of differences in psychosis disorder presentation and manifestation, and differences in response to antipsychotic drug treatment.

Detailed Description

This is a population-based, genetic-association, candidate polymorphism study. It will involve a prospective and a retrospective component. A blood draw or saliva sample will be performed during the participant's admission to BCPP, which may occur at any point during the participant's length of stay. When a participant has been deemed 'Ready for Discharge' by his/her attending psychiatrist at BCPP, a full phenotype will be obtained via retrospective chart review. Genetic analyses and determination of protein levels will be performed after chart review. Following fulfillment of the primary study objective, the remaining blood and saliva samples will be stored in the biobank over the long-term.

Study Timeline

• Study Start: 2014-07
• Study First Submitted: 2014-12-12
• Study First Submitted QC: 2014-12-17
• Study First Posted: 2014-12-23
• Status Verified: 2016-05
• Last Update Submitted: 2016-05-30
• Last Update Posted: 2016-06-01
• Primary Completion: 2018-07
• Study Completion: 2018-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Admission to BCPP.
• Has provided written informed consent.

Read More

Exclusion Criteria

• None.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Participants admitted to BCPP	Blood samples for whole genomic/transcriptomic sequencing	Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing

Primary Outcome Measures

Name	Time	Method
Creation of biorepository of blood samples for future genetic, proteonomic and pharmacogenomic studies.	One visit during participant's stay at BCPP, an expected average of 6 months	A biobank of stored samples will be used to determine the genetic variability in psychosis disorder.

Secondary Outcome Measures

Name	Time	Method
Identification of single-nucleotide polymorphisms (SNPs) in the BDNF and COMT genes	One visit during participant's stay at BCPP, an expected average of 6 months	We will determine if specific genetic variants in BDNF and COMT genes are associated with psychosis disorder severity, symptomology and resolution.
Medical Chart Review	One visit during participant's stay at BCPP, an expected average of 6 months	A medical chart review will be done on hard-copy medical charts at BCPP.

Trial Locations

Locations (1)

University of British Columbia Hospital - BC Psychosis Program; 🇨🇦 Vancouver, British Columbia, Canada